David Alan Campbell Sells 25,000 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction dated Tuesday, December 24th. The stock was sold at an average price of $56.19, for a total value of $1,404,750.00. Following the completion of the transaction, the chief executive officer now directly owns 217,054 shares of the company’s stock, valued at $12,196,264.26. The trade was a 10.33 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

David Alan Campbell also recently made the following trade(s):

• On Tuesday, December 3rd, David Alan Campbell sold 15,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $67.00, for a total value of $1,005,000.00.
• On Monday, November 25th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $51.60, for a total value of $1,290,000.00.
• On Monday, October 28th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $53.54, for a total transaction of $1,338,500.00.

Janux Therapeutics Stock Performance

Shares of JANX stock traded down $1.07 during trading hours on Friday, reaching $54.10. The company had a trading volume of 492,668 shares, compared to its average volume of 784,267. Janux Therapeutics, Inc. has a 12-month low of $7.79 and a 12-month high of $71.71. The company has a market capitalization of $2.84 billion, a price-to-earnings ratio of -46.24 and a beta of 3.29. The stock has a fifty day moving average of $54.43 and a 200-day moving average of $47.43.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The company had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.50 million. The business’s quarterly revenue was down 82.6% on a year-over-year basis. On average, analysts forecast that Janux Therapeutics, Inc. will post -1.35 EPS for the current year.

Wall Street Analyst Weigh In

JANX has been the topic of several recent analyst reports. HC Wainwright increased their price objective on shares of Janux Therapeutics from $63.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. BTIG Research raised their price target on shares of Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a report on Tuesday, December 3rd. UBS Group began coverage on Janux Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $69.00 price objective for the company. Finally, Leerink Partners lifted their price target on Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 3rd. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $89.90.

Institutional Investors Weigh In On Janux Therapeutics

A number of hedge funds have recently modified their holdings of JANX. Janus Henderson Group PLC raised its stake in Janux Therapeutics by 40.0% during the third quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock worth $114,587,000 after purchasing an additional 721,563 shares during the period. Logos Global Management LP increased its holdings in shares of Janux Therapeutics by 400.0% during the 2nd quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock worth $31,418,000 after buying an additional 600,000 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in shares of Janux Therapeutics by 190.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company’s stock worth $17,985,000 after buying an additional 259,445 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Janux Therapeutics by 202.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock valued at $10,639,000 after buying an additional 156,675 shares during the period. Finally, Barclays PLC lifted its holdings in Janux Therapeutics by 496.5% in the third quarter. Barclays PLC now owns 174,061 shares of the company’s stock valued at $7,907,000 after acquiring an additional 144,883 shares during the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.